Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dame Kay Davies, Dr Lee’s Professor of Anatomy here in DPAG, has been working on a clinical trial that today announced a potentially life-changing discovery.

Summit Therapeutics, the drug discovery and development company advancing therapies for rare diseases and infectious diseases, for which Professor Davies is a co-founder, have released the interim results from the trial, PhaseOut DMD, which had been evaluating the effect of ezutromid in patients with Duchenne muscular dystrophy, DMD.

Discoveries show that ezutromid does indeed reduce muscle damage significantly in DMD patients; a total of 14 out of 22 patients showed a decrease in developmental myosin, a biomarker of muscle damage, with five of those patients showing a greater than 40% reduction.

DMD is a progressive muscle wasting disease that affects around 50,000 boys and young men in the developed world. The results from the trial suggest a potential universal treatment for DMD, since there is currently no cure for DMD and life expectancy is into the late twenties.

Professor Davies is delighted at the results from the trial, saying: These data provide the first evidence of utrophin modulation working in patients. If further findings build on this evidence they could establish ezutromid as a universal, disease-modifying treatment and bring hope to all patients and families living with DMD.

Similar stories

New research to radically alter our understanding of synaptic development

Publication Research

A new study from the Molnár group on the role of regulated synaptic vesicular release in specialised synapse formation has made it to the cover of Cerebral Cortex.

Being "in the zone": how waking activity controls sleep need

Publication Research Vyazovskiy Group News

A new study from the Vyazovskiy group suggests that how and where we spend our time while awake impacts how much we need to sleep - it does not only depend on how long we are awake.

New target identified to develop treatment for Abdominal Aortic Aneurysm

Cardiac Theme Publication Research

A new study from the Smart group has shed light on a key regulatory step in the initiation and progression of Abdominal Aortic Aneurysm by revealing the protective role of a previously little known small protein.

Two DPAG pioneers honoured on Sherrington Building Plaques

EDI News Head of Department's News

Honouring the heritage of pioneering physiologists Sir Charles Sherrington and Florence Buchanan. "Commemorating both pioneers together highlights the importance of advocacy and mentoring that was evident over a century ago as equality was championed." (David Paterson)